Table 1. Immunolabeling of TGF-β-expressing cells.

	TGF-β1			TGF-β2		TGF-β3
	layer II	layer V	CP	layer II	layer V	layer II
Number of TGF-β cells/0.08 mm2	18.3±4.9	16.7±3.5	20.5±4.5	18.3±4.2	17.0±3.9	14.0±4.5
Immunolabeled cells in the % of TGF-β cells
NeuN	3.7±2.8	4.7±3.3	5.7±3.9	87,1±3,8	84,8±2,7	81,1±3.5
GFAP	26.3±2.8	21.6±6.2	22.2±4.4	4.2±2.3	4.0±2.1	9.3±5.8
Iba1	93.7±3.4	94.0±4.6	96.0±4.1	3.1±2.6	3.5±2.4	6.7±3.4
Hsp70	7.2±2.2	4.8±3.9	5.5±2.9	76.3±7.4	69.2±8.9	–
Fos	4.1±2.2	4.7±3.3	5.2±2.7	90.2±3.8	91.9±4.6	–
ATF-3	8.4±1.9	7.1±2.6	8.5±4.1	2.8±1.9	4.3±2.9	–

Data on TGF-β1 is presented in 3 different locations, layer II and V of the cerebral cortex and the caudate putamen (CP). Because TGF-β2 is not expressed in the caudate putamen, TGF-β2-expressing cells were only counted in the cerebral cortex. Similarly, data on TGF-β3 are provided only for layer II of the cerebral cortex. In the upper row, the total number of TGF-β-expressing cells counted in a 400×200 µm rectangular-shaped area immediately outside the lesion is shown. The number of double-labeled cells was also counted in the same field, and the calculated ratios were averaged. One-way ANOVA did not indicate significant differences between brain regions for any of the markers.